Jump Financial LLC Makes New Investment in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Jump Financial LLC acquired a new position in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYXFree Report) in the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 29,060 shares of the company’s stock, valued at approximately $72,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Arizona State Retirement System raised its position in shares of Ventyx Biosciences by 9.8% in the 3rd quarter. Arizona State Retirement System now owns 11,671 shares of the company’s stock worth $405,000 after acquiring an additional 1,043 shares in the last quarter. Teacher Retirement System of Texas increased its holdings in Ventyx Biosciences by 13.4% in the third quarter. Teacher Retirement System of Texas now owns 11,642 shares of the company’s stock worth $404,000 after purchasing an additional 1,376 shares in the last quarter. JSF Financial LLC bought a new stake in Ventyx Biosciences in the third quarter worth approximately $208,000. Rafferty Asset Management LLC acquired a new position in Ventyx Biosciences in the third quarter valued at approximately $209,000. Finally, Swiss National Bank boosted its holdings in shares of Ventyx Biosciences by 9.5% during the 3rd quarter. Swiss National Bank now owns 90,200 shares of the company’s stock worth $3,133,000 after buying an additional 7,800 shares in the last quarter. Institutional investors and hedge funds own 97.88% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on VTYX shares. Wells Fargo & Company upgraded shares of Ventyx Biosciences from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $7.00 to $16.00 in a research report on Tuesday, March 12th. Oppenheimer raised shares of Ventyx Biosciences from a “market perform” rating to an “outperform” rating and set a $12.00 price objective on the stock in a research report on Tuesday, March 12th. Lifesci Capital upgraded Ventyx Biosciences from a “market perform” rating to an “outperform” rating in a research note on Wednesday, February 28th. Finally, Canaccord Genuity Group dropped their price target on Ventyx Biosciences from $16.00 to $15.00 and set a “buy” rating on the stock in a research note on Wednesday, March 13th. Four analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $21.75.

View Our Latest Research Report on VTYX

Ventyx Biosciences Price Performance

NASDAQ:VTYX opened at $4.81 on Friday. Ventyx Biosciences, Inc. has a one year low of $1.87 and a one year high of $40.58. The company has a market cap of $339.11 million, a PE ratio of -1.48 and a beta of 0.48. The firm has a 50-day moving average of $4.75 and a 200-day moving average of $3.98.

Ventyx Biosciences (NASDAQ:VTYXGet Free Report) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.62) EPS for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.05. During the same period in the prior year, the business earned ($0.68) EPS. On average, equities research analysts expect that Ventyx Biosciences, Inc. will post -2.31 earnings per share for the current fiscal year.

Ventyx Biosciences Company Profile

(Free Report)

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

Featured Stories

Want to see what other hedge funds are holding VTYX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ventyx Biosciences, Inc. (NASDAQ:VTYXFree Report).

Institutional Ownership by Quarter for Ventyx Biosciences (NASDAQ:VTYX)

Receive News & Ratings for Ventyx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventyx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.